Recently, China based Wuxi Hisky Medical Technologies Co., Ltd. has successfully launched its new brand iLivTouch based on the MigTE technology. "On the increasingly competitive market, cycles of technological innovation are key to maintaining our leading position," said Dr. Shao Jinhua, CEO of HISKY. "The new series of products, which are equipped with several worldwide uniquely patented technologies jointly developed by HISKY and Tsinghua University, have made great breakthroughs in terms of detection accuracy, ease of operations, and clinical function." In recent years, China's medical device market has maintained rapid growth. According to the data from iiMedia Research, the average annual growth rate of China's medical device market maintains at about 20%, and the market size is expected to exceed RMB 900 billion yuan by 2022. Many excellent medical device companies in China have invested in this huge market, so market competition has intensified. iLivTouch products contain a number of leading technologies, including dual-mode cross-border fusion probes, multi-channel tissue information scanning, high-end color ultrasound assisted diagnosis and ultra-clear common-frequency dual display. Compared with similar products in the world, HISKY's products have significantly improved the accuracy of positioning and measurement. In addition, the unique tissue RF signal capability of the iLivTouch series will better support clinical experts. HISKY's liver fibrosis detection products (FT series) have been have been installed in more than 1,000 hospitals and institutions across the country, serving nearly 10 million people. Jia Jidong, professor of Capital Medical University and Beijing Friendship Hospital, and Lu Lungen, professor of Shanghai First People's Hospital, are currently carrying out medical practices in multiple hospitals, applying HISKY's non-invasive diagnostic system to the clinic practices, accumulating big data, and contributing to further technical improvement.